Autografting followed by a reduced-intensity conditioning unrelated donor cord blood transplantation for a patient with refractory multiple myeloma: successful engraftment with minimal toxicity.
We report on a 59-yr-old man with recurrent multiple myeloma. To reduce treatment-related mortality, while retaining the cytoreductive effects of high-dose chemotherapy, as well as graft vs. myeloma effect, we used a reduced-intensity conditioning umbilical cord blood (CB) transplantation following high-dose chemotherapy with autologous stem cell transplantation support. This patient was engrafted rapidly and extramedullary toxicities were acceptable. Although he had local recurrence in the right calf on day +130 after the CB transplantation, the tumor was successfully treated with radiation therapy, and he is alive and well at present (day +480).
Ando
Toshihiko
T
Third Department of Internal Medicine, Yamaguchi University School of Medicine, Yamaguchi, Japan.
Yujiri
Toshiaki
T
Tominaga
Takayuki
T
Shinya
Sonoe
S
Takahashi
Toru
T
Nomiyama
Jun
J
Seguchi
Masato
M
Matsubara
Atsushi
A
Fujii
Yasuhiko
Y
Tanizawa
Yukio
Y
D036101:Cord Blood Stem Cell Transplantation; D006085:Graft Survival; D020350:Graft vs Tumor Effect; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D012074:Remission Induction; D014019:Tissue Donors; D018183:Transplantation Chimera; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous